explore -WSS

explore

author：entertainment 2025-09-28 00:53:50 - browse：4549

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Unmasking the 'centricity' illusion in clinical trials

focus

WSS

Achieving telehealth equity for people with hearing loss

UPS workers' union leader explains what's at stake as strike edges closer

Pharma’s losing bet in New Jersey

With fresh data, a dynamic duo powers Eli Lilly to new heights

New research sheds light on how often breast cancer is overdiagnosed

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Rare Northern Lights show in US this week: Where and how to see it

Wildfire smoke exposes gaps in outdoor worker protections

With fresh data, a dynamic duo powers Eli Lilly to new heights

Malaria cases in Florida and Texas: Here’s what you need to know

How corporate America is slashing DEI workers amid backlash to diversity programs

Wildfire smoke exposes gaps in outdoor worker protections

Rare Northern Lights show in US this week: Where and how to see it

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why some fertility treatments produce more boy babies

hotspot

Why we need mandatory labeling of GMO products

The Bio Revolution is changing business and society

The Bio Revolution is changing business and society

U.S. death rates show how politics are affecting public health

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

The world needs the new pandemic treaty

hotspot

entertainment

focus

hotspot